Investigating KLF2 as a protective target for diabetic kidney disease
Official title: KLF2 is a novel endoprotective target for DKD
Funded at Icahn School of Medicine at Mount Sinai · NIH-11194403 · Data updated 2026-11-12
This study is looking at how a special protein called KLF2 can help protect both the kidneys and the heart in people with diabetic kidney disease, with the goal of finding new treatments to improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 20, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $721,246 |
| NIH project number | 5R01DK141510-02 |
| Project ID | NIH-11194403 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diabetic kidney disease who may also be at risk for cardiovascular disease.
✕Less likely to help
Patients without diabetic kidney disease or those with other unrelated kidney conditions may not benefit from this research.
What this research studies
This research focuses on diabetic kidney disease (DKD) and its link to cardiovascular disease (CVD), aiming to develop new treatments that provide protection for both the kidneys and the heart. The study examines the role of a specific protein, KLF2, which is involved in protecting endothelial cells from injury caused by diabetes. By understanding how KLF2 functions and its regulatory mechanisms, the research seeks to identify potential therapeutic strategies that could improve patient outcomes in those suffering from DKD and related cardiovascular issues.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly reduce the risk of cardiovascular complications in patients with diabetic kidney disease.
How similar studies have gone: Previous research has shown promising results in targeting KLF2 for protective effects in cardiovascular conditions, suggesting a potential for success in this novel application.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: He, John Cijiang — Icahn School of Medicine at Mount Sinai
- Study coordinator: He, John Cijiang
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genetically Validated PCOS Subtypes for Better Diagnosis and Risk Stratification
Aimed at women with polycystic ovary syndrome (PCOS), this project uses genetic data and patient characteristics to define distinct PCOS subtypes and improve how we diagnose and estimate risk.
-
Closed-loop control of interneuron timing to influence seizures and memory in epilepsy
A study tests a brain-quieting system that uses light to precisely time certain brain cells in epilepsy-prone mice to see if this can lessen seizures and improve memory.
-
Understanding why some brain regions and cells accumulate tau in Alzheimer’s and related diseases
Researchers are studying why certain brain areas and neuron types accumulate tau protein in Alzheimer’s and related conditions, and how this leads to brain changes and symptoms.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
Aging and brain injury connection: learning how late-life TBI relates to Alzheimer’s and related dementias
This grant looks at whether traumatic brain injuries in people 65 and older are linked to Alzheimer’s disease and related dementias, using a large, harmonized set of long-term aging studies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.